Association Between Metabolic Syndrome and Kidney Cancer Risk: a Prospective Cohort Study

Overview

Journal Lipids Health Dis

Publisher Biomed Central

Specialties Biochemistry
Endocrinology

Date 2024 May 17

PMID 38760801

Authors

Lin Wang

Han Du

Chao Sheng

Hongji Dai

Kexin Chen

Affiliations

Soon will be listed here.

Abstract

Background: Kidney cancer has become known as a metabolic disease. However, there is limited evidence linking metabolic syndrome (MetS) with kidney cancer risk. This study aimed to investigate the association between MetS and its components and the risk of kidney cancer.

Methods: UK Biobank data was used in this study. MetS was defined as having three or more metabolic abnormalities, while pre-MetS was defined as the presence of one or two metabolic abnormalities. Hazard ratios (HRs) and 95% confidence intervals (CIs) for kidney cancer risk by MetS category were calculated using multivariable Cox proportional hazards models. Subgroup analyses were conducted for age, sex, BMI, smoking status and drinking status. The joint effects of MetS and genetic factors on kidney cancer risk were also analyzed.

Results: This study included 355,678 participants without cancer at recruitment. During a median follow-up of 11 years, 1203 participants developed kidney cancer. Compared to the metabolically healthy group, participants with pre-MetS (HR= 1.36, 95% CI: 1.06-1.74) or MetS (HR= 1. 70, 95% CI: 1.30-2.23) had a significantly greater risk of kidney cancer. This risk increased with the increasing number of MetS components (P for trend < 0.001). The combination of hypertension, dyslipidemia and central obesity contributed to the highest risk of kidney cancer (HR= 3.03, 95% CI: 1.91-4.80). Compared with participants with non-MetS and low genetic risk, those with MetS and high genetic risk had the highest risk of kidney cancer (HR= 1. 74, 95% CI: 1.41-2.14).

Conclusions: Both pre-MetS and MetS status were positively associated with kidney cancer risk. The risk associated with kidney cancer varied by combinations of MetS components. These findings may offer novel perspectives on the aetiology of kidney cancer and assist in designing primary prevention strategies.

Citing Articles

Metabolic syndrome and increased susceptibility to renal cell carcinoma - a meta-analysis.

Zhou Y, Chen Y, Yang H, Xu Z, Zhuang J, Bian Q BMC Nephrol. 2025; 26(1):102.

PMID: 40012054 PMC: 11863896. DOI: 10.1186/s12882-025-04013-6.

Research progress on the correlation between obesity and the occurrence and development of kidney cancer: a narrative review.

Kang L, Chen X, Qi P, Ma Z, Han D, Zhang X Transl Cancer Res. 2024; 13(10):5678-5690.

PMID: 39525017 PMC: 11543094. DOI: 10.21037/tcr-24-744.

Metabolic syndrome and cancer risk: a two-sample Mendelian randomization study of European ancestry.

Zhou L, Gao H, Zhang J, Xu Q, Wang Q, Wang L Int J Surg. 2024; 111(1):311-321.

PMID: 39051916 PMC: 11745630. DOI: 10.1097/JS9.0000000000001926.

References

Nam G, Cho K, Han K, Kim C, Han B, Cho S . Obesity, abdominal obesity and subsequent risk of kidney cancer: a cohort study of 23.3 million East Asians. Br J Cancer. 2019; 121(3):271-277. PMC: 6738324. DOI: 10.1038/s41416-019-0500-z. View

Hsieh J, Purdue M, Signoretti S, Swanton C, Albiges L, Schmidinger M . Renal cell carcinoma. Nat Rev Dis Primers. 2017; 3:17009. PMC: 5936048. DOI: 10.1038/nrdp.2017.9. View

Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D . Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012; 35(11):2402-11. PMC: 3476894. DOI: 10.2337/dc12-0336. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Alberti K, Eckel R, Grundy S, Zimmet P, Cleeman J, Donato K . Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation;.... Circulation. 2009; 120(16):1640-5. DOI: 10.1161/CIRCULATIONAHA.109.192644. View

Siegel R, Miller K, Fuchs H, Jemal A . Cancer Statistics, 2021. CA Cancer J Clin. 2021; 71(1):7-33. DOI: 10.3322/caac.21654. View

Lewis C, Vassos E . Polygenic risk scores: from research tools to clinical instruments. Genome Med. 2020; 12(1):44. PMC: 7236300. DOI: 10.1186/s13073-020-00742-5. View

Scelo G, Larose T . Epidemiology and Risk Factors for Kidney Cancer. J Clin Oncol. 2018; :JCO2018791905. PMC: 6299342. DOI: 10.1200/JCO.2018.79.1905. View

Dregan A, Rayner L, Davis K, Bakolis I, Arias de la Torre J, Das-Munshi J . Associations Between Depression, Arterial Stiffness, and Metabolic Syndrome Among Adults in the UK Biobank Population Study: A Mediation Analysis. JAMA Psychiatry. 2020; 77(6):598-606. PMC: 6990710. DOI: 10.1001/jamapsychiatry.2019.4712. View

10.

Liang Y, Chen J, Peng M, Zhou J, Chen X, Tan X . Association between sleep duration and metabolic syndrome: linear and nonlinear Mendelian randomization analyses. J Transl Med. 2023; 21(1):90. PMC: 9903442. DOI: 10.1186/s12967-023-03920-2. View

11.

Archambault A, Su Y, Jeon J, Thomas M, Lin Y, Conti D . Cumulative Burden of Colorectal Cancer-Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer. Gastroenterology. 2019; 158(5):1274-1286.e12. PMC: 7103489. DOI: 10.1053/j.gastro.2019.12.012. View

12.

Haggstrom C, Rapp K, Stocks T, Manjer J, Bjorge T, Ulmer H . Metabolic factors associated with risk of renal cell carcinoma. PLoS One. 2013; 8(2):e57475. PMC: 3585341. DOI: 10.1371/journal.pone.0057475. View

13.

Choe J, Hyun J, Kim B, Han K . Influence of Metabolic Syndrome on Cancer Risk in HBV Carriers: A Nationwide Population Based Study Using the National Health Insurance Service Database. J Clin Med. 2021; 10(11). PMC: 8198770. DOI: 10.3390/jcm10112401. View

14.

Eckel R, Grundy S, Zimmet P . The metabolic syndrome. Lancet. 2005; 365(9468):1415-28. DOI: 10.1016/S0140-6736(05)66378-7. View

15.

Harrison H, Li N, Saunders C, Rossi S, Dennis J, Griffin S . The current state of genetic risk models for the development of kidney cancer: a review and validation. BJU Int. 2022; 130(5):550-561. PMC: 9790357. DOI: 10.1111/bju.15752. View

16.

Henrion M, Purdue M, Scelo G, Broderick P, Frampton M, Ritchie A . Common variation at 1q24.1 (ALDH9A1) is a potential risk factor for renal cancer. PLoS One. 2015; 10(3):e0122589. PMC: 4380462. DOI: 10.1371/journal.pone.0122589. View

17.

Van Hemelrijck M, Garmo H, Hammar N, Jungner I, Walldius G, Lambe M . The interplay between lipid profiles, glucose, BMI and risk of kidney cancer in the Swedish AMORIS study. Int J Cancer. 2011; 130(9):2118-28. DOI: 10.1002/ijc.26212. View

18.

Cheung B, Li C . Diabetes and hypertension: is there a common metabolic pathway?. Curr Atheroscler Rep. 2012; 14(2):160-6. PMC: 3314178. DOI: 10.1007/s11883-012-0227-2. View

19.

Fahed G, Aoun L, Zerdan M, Allam S, Zerdan M, Bouferraa Y . Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci. 2022; 23(2). PMC: 8775991. DOI: 10.3390/ijms23020786. View

20.

Jiang R, Wang X, Li Z, Cai H, Sun Z, Wu S . Association of metabolic syndrome and its components with the risk of urologic cancers: a prospective cohort study. BMC Urol. 2023; 23(1):150. PMC: 10514929. DOI: 10.1186/s12894-023-01324-4. View